Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

GMED's strong synergies from the NuVasive merger and robust performance in the musculoskeletal solutions space bode well for investors.

BofA analyst Craig Bijou upgraded Globus Medical (GMED) to Neutral from Underperform with a price target of $97, up from $80, after the company preannounced Q4 revenue that was 3% above the Street ...

The Global MedTech Industry Outlook for 2025 aims to provide insights into the anticipated performance of the MedTech sectors ...

With the proliferation of remote proceedings that was borne out of the recent global pandemic, the advent of trials playing ...

In the third quarter, Globus' proforma musculoskeletal revenues (assuming NuVasive revenue in the year-ago period) improved 5.4%, marking it the fourth consecutive quarter of pro forma ...

Electromagnetic Surgical Navigation System Market The global electromagnetic surgical navigation system <a target=_blank href= ...

Taiwan Coast Guard says ship that allegedly cut cable crewed by Chinese Request To Download Free Sample of This Strategic Report @ ...

An unconventional approach to high-yield credit comes at a price. Our research team assigns Negative ratings to strategies they’re confident will underperform a relevant index, or most peers ...